10-Q: Azitra Inc. Reports First Quarter 2024 Results, Cites Ongoing Clinical Trial Progress and Financial Challenges

Azitra Inc. reported a net loss of $2.9 million for the first quarter of 2024, while highlighting progress in clinical trials and ongoing financial uncertainties.

Summary

• Azitra Inc., a biopharmaceutical company focused on precision dermatology, reported a net loss of $2.9 million for the first quarter of 2024, compared to a net loss of $2.5 million for the same period in 2023.
• The company's operating expenses increased significantly, with general and administrative costs rising by 77% to $1.5 million and research and development expenses increasing by 78% to $1.5 million.
• Revenue from a related party decreased to $0 from $113,300 in the first quarter of 2023 due to reduced reimbursable development costs.
• Azitra completed a follow-on public offering in February 2024, raising $4.3 million in net proceeds.
• As of March 31, 2024, the company had total assets of $6.1 million and working capital of $2.3 million, including $3.0 million in cash and cash equivalents.
• Management has expressed substantial doubt about the company's ability to continue as a going concern due to ongoing losses and the need for additional capital.
• The company is advancing its lead product candidates, ATR-12 for Netherton syndrome and ATR-04 for EGFRi-associated rash, through clinical trials.
• Initial safety results for the Phase 1b clinical trial of ATR-12 are expected in the second half of 2024, and a Phase 1b trial for ATR-04 is planned for the fourth quarter of 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical trials and a successful capital raise, the significant increase in losses, the decrease in revenue, and the going concern warning from management weigh heavily on the sentiment. The material weakness in internal controls also adds to the negative sentiment.

Positives

• The company successfully completed a follow-on public offering, raising $4.3 million in net proceeds.
• Azitra has commenced operating activities for its Phase 1b clinical trial of ATR-12.
• The company is progressing towards a Phase 1b trial for ATR-04, expected to start in the fourth quarter of 2024.
• Azitra has a proprietary platform and microbial library of approximately 1,500 unique bacterial strains for developing therapeutic products.

Negatives

• The company experienced a net loss of $2.9 million in Q1 2024, an increase from $2.5 million in Q1 2023.
• Operating expenses increased significantly, with general and administrative costs up 77% and research and development expenses up 78%.
• Service revenue from a related party decreased to $0 from $113,300 in the same period last year.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company identified a material weakness in internal controls related to segregation of accounting functions.

Risks

• The company's ability to continue as a going concern is in doubt due to ongoing losses and the need for additional capital.
• There is no guarantee that the company will be able to secure additional financing on commercially reasonable terms.
• The company is subject to risks common to the pharmaceutical industry, including development of new technologies by competitors, dependence on key personnel, and regulatory compliance.
• The company's clinical trials may not be successful, and product candidates may not receive regulatory approval.
• The company's reliance on third-party manufacturers poses a risk to its supply chain.

Future Outlook

The company expects to report initial safety results for the Phase 1b clinical trial of ATR-12 in the second half of 2024 and plans to commence a Phase 1b trial of ATR-04 in the fourth quarter of 2024. The company also plans to complete lead optimization and IND-enabling studies for ATR-01 in 2024, with an IND filing targeted for the second half of 2025. The company anticipates that research and development expenses will significantly increase in the future due to planned clinical trial activity and continued development of product candidates. The company intends to seek additional funds through various financing sources.

Management Comments

• Management has identified conditions and events that create substantial doubt about the ability of the Company to continue as a going concern for twelve months from the date that the financial statements are available to be issued.
• Management plans to continue to raise funds through equity and debt financing to fund operating and working capital needs.
• Management intends to increase staffing within our accounting infrastructure sufficient to facilitate proper segregation of accounting functions and to enable appropriate review of our internally prepared financial statements.

Industry Context

Azitra is operating in the competitive biopharmaceutical industry, specifically focused on precision dermatology. The company is leveraging its proprietary microbial library and genetic engineering technologies to develop novel therapies. The company's focus on genetically engineered bacteria for therapeutic use in dermatology is a relatively new approach, and the company is competing with both traditional pharmaceutical companies and other biotech firms in the space. The company's partnerships with academic institutions and its collaboration with Bayer are strategic moves to enhance its research and development capabilities and market reach.

Comparison to Industry Standards

• Azitra's financial results are typical of an early-stage clinical biopharmaceutical company, with significant operating losses and reliance on external funding.
• Compared to other companies in the biotech sector, Azitra's cash burn rate is relatively high, reflecting the costs associated with clinical trials and research and development.
• Companies like Dermavant Sciences and Arcutis Biotherapeutics, which are also focused on dermatology, have similar challenges in terms of funding and clinical development.
• Azitra's approach of using genetically engineered bacteria is unique compared to traditional small molecule or antibody-based therapies, which could provide a competitive advantage if successful.
• The company's collaboration with Bayer is similar to other biotech companies that partner with larger pharmaceutical firms for development and commercialization.

Corporate Governance

Related Party Transactions

• Total related party revenue was $0 for the three months ended March 31, 2024, compared to $113,300 for the same period in 2023.
• Accounts receivable due from the related party was $0 at March 31, 2024, compared to $90,000 at December 31, 2023.
• In September 2022 the Company entered into a convertible promissory note totaling $4,350,000 of which $4,000,000 was attributable to an entity who was also an investor in the Companys Series A, A-1, and B Preferred Stock financing.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment due to the company's going concern status.
• Employees may be concerned about job security given the company's financial challenges.
• Customers and partners may be concerned about the company's ability to deliver on its product development plans.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company expects to report initial safety results of the Phase 1b clinical trial for ATR-12 in the second half of 2024.
• The company plans to commence a Phase 1b trial of ATR-04 in the fourth quarter of 2024.
• The company is planning to complete lead optimization and IND-enabling studies for ATR-01 in 2024, with an IND filing targeted for the second half of 2025.
• The company intends to seek additional funds through various financing sources.

Key Dates

Keywords

biopharmaceutical, dermatology, clinical trials, Netherton syndrome, EGFRi, microbial, genetic engineering, financing, going concern, ATR-12, ATR-04